Vaccination Approach Transforms Respiratory Disease Prevention
- A new vaccine developed by Trinity College dublin researchers offers a potential breakthrough in preventing and controlling respiratory infections like whooping cough by reducing bacterial transmission.
- Researchers at Trinity College Dublin have announced a notable advancement in vaccination technology with the advancement of a nasal vaccine against whooping cough.
- The research, spearheaded by Professor Kingston Mills and dr.
“`html
Novel Nasal Vaccine Shows Promise in Curbing Whooping Cough Transmission
Table of Contents
A new vaccine developed by Trinity College dublin researchers offers a potential breakthrough in preventing and controlling respiratory infections like whooping cough by reducing bacterial transmission.
Breakthrough in Whooping Cough Vaccination
Researchers at Trinity College Dublin have announced a notable advancement in vaccination technology with the advancement of a nasal vaccine against whooping cough. Published in Nature Microbiology on November 10, 2025, the study details how their nasally-delivered, antibiotic-inactivated Bordetella pertussis (AIBP) vaccine not only prevents severe disease but also demonstrably reduces bacterial transmission. Nature Microbiology
The research, spearheaded by Professor Kingston Mills and dr. Davoud Jazayeri from Trinity’s School of Biochemistry and Immunology, introduces a needle-free mucosal vaccine platform.This platform aims to induce lasting local immunity directly at the site of infection,offering a perhaps transformative approach to respiratory bacterial vaccine development.
How the AIBP Vaccine Works
Conventional whooping cough vaccines, typically administered via injection, primarily focus on preventing severe illness in vaccinated individuals. However, they often fall short in preventing the spread of the Bordetella pertussis bacteria to others. The AIBP vaccine tackles this issue by stimulating a robust immune response within the nasal passages – the primary entry point for the bacteria.
The vaccine utilizes an inactivated form of the Bordetella pertussis bacteria, treated with antibiotics to ensure safety. Delivering the vaccine nasally mimics the natural route of infection, prompting the mucosal immune system to mount a more effective defense.This localized immunity is crucial for intercepting the bacteria before it can establish an infection and be transmitted to others.
The Importance of Reducing Transmission
Reducing bacterial transmission is a critical goal in public health, particularly for diseases like whooping cough. While vaccination rates have increased globally, outbreaks still occur, frequently enough affecting vulnerable populations like infants too young to be fully vaccinated.
According to the Centers for Disease Control and Prevention (CDC), there were 2,825 cases of pertussis reported in the United States in 2023.A vaccine that effectively curtails transmission could significantly lower these numbers and protect those most at risk. The CDC also notes that waning immunity from the childhood DTaP vaccine series is a contributing factor to outbreaks in adolescents and adults.
| Year | reported Cases (US) |
|---|---|
| 2020 | 1,384 |
| 2021 | 2,247 |